Storia in 13 fonti

Eli Lilly agrees to $3.8B psychedelic buy

The AtaiBeckley acquisition would be the largest psychedelic deal to date.

Raccontata da

zerohedge.com

biopharmadive.com

benzinga.com

economictimes.indiatimes.com

www1.folha.uol.com.br+1 altre

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

axios.comStai leggendo1 mese fa

Eli Lilly agrees to $3.8B psychedelic buy

The AtaiBeckley acquisition would be the largest psychedelic deal to date.

originale

biopharmadive.com

Timeline cronologica

mercoledì 15 luglio 2026·zerohedge.com
Big Pharma Just Started Buying Up Psychedelic Companies
Massive validation for psychedelics…the M&A race has officially begun...
giovedì 16 luglio 2026·biopharmadive.com
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.

1 mese fa

Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics

The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.

Leggi questa versione → originale

endpoints.news1 mese fa

Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley

Eli Lilly will buy psychedelic drug developer AtaiBeckley for $2.8 billion upfront, showing big pharma’s increasing interest in psychedelics.

Leggi questa versione → originale

statnews.com1 mese fa

Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley

Eli Lilly is buying the psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront, a move that will expand its neuroscience pipeline.

Leggi questa versione → originale

cnbc.com1 mese fa

Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction

The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.

Leggi questa versione → originale

economictimes.indiatimes.com1 mese fa

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal

Eli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and other mental health issues. The acquisition includes AtaiBeckley's lead candidate, BPL-003,…

Leggi questa versione → originale

giovedì 16 luglio 2026·

benzinga.com

AtaiBeckley (ATAI) Stock Skyrockets 65% After-Hours on Eli Lilly Acquisition Talks - Eli Lilly (NYSE:LLY)

AtaiBeckley shares jumped 64.70% after hours following reports that Eli Lilly is in talks to acquire the psychedelic drugmaker at a premium.

giovedì 16 luglio 2026·

economictimes.indiatimes.com

Weight-loss drugmaker Lilly nears $1.97 bn AtaiBeckley's acquisition: Report

Eli Lilly is reportedly negotiating to acquire psychedelic drugmaker AtaiBeckley. AtaiBeckley shares experienced a significant surge following the news of these discussions. The…

giovedì 16 luglio 2026·

cnbc.com

Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction

The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.

giovedì 16 luglio 2026·

endpoints.news

Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley

Eli Lilly will buy psychedelic drug developer AtaiBeckley for $2.8 billion upfront, showing big pharma’s increasing interest in psychedelics.

giovedì 16 luglio 2026·

milanofinanza.it

Eli Lilly punta sugli psichedelici: acquisirà AtaiBeckley per 2,8 miliardi di dollari | MilanoFinanza News

L’operazione consente al gruppo farmaceutico di mettere le mani su BPL-003, uno spray nasale a base di DMT in fase 3 di sperimentazione per la depressione resistente. Le azioni di…

giovedì 16 luglio 2026·

statnews.com

Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley

Eli Lilly is buying the psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront, a move that will expand its neuroscience pipeline.

giovedì 16 luglio 2026·

economictimes.indiatimes.com

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal

Eli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and other mental health issues. The acquisition includes…

giovedì 16 luglio 2026·

zerohedge.com

The Big Pharma Psychedelic Buyout Spree Has Begun

"Eli Lilly is in talks to acquire AtaiBeckley, one of the leading developers of next-generation psychedelic therapies."

giovedì 16 luglio 2026·

forbes.it

Eli Lilly scommette sulla salute mentale: acquisita AtaiBeckley per 2,8 miliardi di dollari

Eli Lilly acquisisce AtaiBeckley per 2,8 miliardi di dollari per sviluppare trattamenti contro la depressione resistente

giovedì 16 luglio 2026·

manager-magazin.de

AtaiBeckley: Eli Lilly kauft Psychedelika-Entwickler von Christian Angermayer

Psychedelische Substanzen versprechen offenbar gute Geschäfte. Jetzt kauft der Pharmakonzern Eli Lilly den US-Spezialisten AtaiBeckley für rund 4 Milliarden Dollar. Größter…

giovedì 16 luglio 2026·

axios.com

Eli Lilly agrees to $3.8B psychedelic buy

The AtaiBeckley acquisition would be the largest psychedelic deal to date.

giovedì 16 luglio 2026·

benzinga.com

AtaiBeckley Shares Surge as Eli Lilly Seals $3.8B Acquisition Deal - Eli Lilly (NYSE:LLY), AtaiBeckley (N

Lilly will acquire AtaiBeckley in a deal worth up to $3.8 billion, adding late-stage depression therapies to its mental health pipeline.

venerdì 17 luglio 2026·

www1.folha.uol.com.br

Dona da Mounjaro compra empresa que produz antidepressivos por US$ 3,8 bilhões

Eli Lilly adquire AtaiBeckley, que está estudando spray nasal que utiliza alucinógeno

venerdì 17 luglio 2026·

oglobo.globo.com

Fabricante do Monjauro fecha acordo de US$ 3,8 bi para comprar empresa de medicamentos psicodélicos

Acordo reforça a presença de longa data da Lilly na área de neurociências, segmento no qual a empresa revolucionou o tratamento da depressão há cerca de três décadas com o…

domenica 19 luglio 2026·

cnbc.com

The market for psychedelic drugs to treat mental health conditions gets a big buy signal

Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of medications for treating mental health.

Eli Lilly agrees to $3.8B psychedelic buy

Timeline cronologica

Big Pharma Just Started Buying Up Psychedelic Companies

Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics

Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics

Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley

Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley

Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal

AtaiBeckley (ATAI) Stock Skyrockets 65% After-Hours on Eli Lilly Acquisition Talks - Eli Lilly (NYSE:LLY)

Weight-loss drugmaker Lilly nears $1.97 bn AtaiBeckley's acquisition: Report

Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction

Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley

Eli Lilly punta sugli psichedelici: acquisirà AtaiBeckley per 2,8 miliardi di dollari | MilanoFinanza News

Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley

Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal

The Big Pharma Psychedelic Buyout Spree Has Begun

Eli Lilly scommette sulla salute mentale: acquisita AtaiBeckley per 2,8 miliardi di dollari

AtaiBeckley: Eli Lilly kauft Psychedelika-Entwickler von Christian Angermayer

Eli Lilly agrees to $3.8B psychedelic buy

AtaiBeckley Shares Surge as Eli Lilly Seals $3.8B Acquisition Deal - Eli Lilly (NYSE:LLY), AtaiBeckley (N

Dona da Mounjaro compra empresa que produz antidepressivos por US$ 3,8 bilhões

Fabricante do Monjauro fecha acordo de US$ 3,8 bi para comprar empresa de medicamentos psicodélicos

The market for psychedelic drugs to treat mental health conditions gets a big buy signal